Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Long-Term Deferred Tax (2021 - 2025)

Bioventus' Long-Term Deferred Tax history spans 3 years, with the latest figure at $4.7 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax fell 35.84% year-over-year to $4.7 million; the TTM value through Sep 2025 reached $4.7 million, down 35.84%, while the annual FY2024 figure was $4.7 million, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $4.7 million in Q3 2025 per BVS's latest filing, roughly flat from $4.7 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $7.4 million in Q3 2024 to a low of $481000.0 in Q2 2021.
  • Average Long-Term Deferred Tax over 3 years is $3.5 million, with a median of $4.7 million recorded in 2024.
  • The largest YoY upside for Long-Term Deferred Tax was 31.07% in 2025 against a maximum downside of 35.84% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $481000.0 in 2021, then skyrocketed by 886.49% to $4.7 million in 2024, then changed by 0.0% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Long-Term Deferred Tax are $4.7 million (Q3 2025), $4.7 million (Q2 2025), and $4.7 million (Q1 2025).